Overview

Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of DDI

Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
Evaluation and validation of metabolic markers for the assessment of CYP3A activity and prediction of drug-drug interaction in Korean healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Hydroxyitraconazole
Itraconazole
Midazolam
Rifampin